Can the use of bone marrow parameters improve the efficacy of risk prediction scores in chronic myeloid leukemia in imatinib era??

Abstract Introduction Many attempts have been made to develop risk prediction scores for chronic myeloid leukemia in chronic phase (CML-CP) to identify the subgroup with poorer response to therapy to intensify treatment modality early. As bone marrow (BM) provides a more sensitive reflection of the...

Ausführliche Beschreibung